Prostate Cell News Volume 9.28 | Jul 27 2018

TOP STORY

Stromal Epigenetic Alterations Drive Metabolic and Neuroendocrine Prostate Cancer Reprogramming

Investigators found that prostate cancer patients on androgen signaling deprivation therapy (ADT) with therapeutic resistance had elevated blood glutamine levels compared to those with therapeutically responsive disease. Identification of epigenetic regulation of RAS activity in prostatic cancer-associated prostatic fibroblasts revealed RASAL3 as a sensor for metabolic and neuroendocrine reprogramming in prostate cancer patients failing ADT. [J Clin Invest] Abstract | Full Article

(Ranked by impact factor of the journal)

Nuclear Receptor ERRα and Transcription Factor ERG Form a Reciprocal Loop in the Regulation of TMPRSS2:ERG Fusion Gene in Prostate Cancer

Scientists showed that up-regulation of nuclear receptor estrogen-related receptor alpha (ERRα) was closely associated with the oncogenic transcription factor ERG expression in prostate cancer, and their increased coexpression patterns were closely associated with high Gleason scores and metastasis in patients. [Oncogene] Full Article

Co-Targeting the Cell Intrinsic and Microenvironment Pathways of Prostate Cancer by PI3Kα/β/δ Inhibitor BAY1082439

The authors found that not only the PI3Kα- and PI3Kβ-isoforms, but also PI3Kδ are associated with the epithelial-mesenchymal transition, a critical process distinguishing indolent from aggressive prostate cancer. [Mol Cancer Ther] Abstract

MTA1 Drives Malignant Progression and Bone Metastasis in Prostate Cancer

Investigators report the role of metastasis-associated protein 1 (MTA1) in prostate cancer progression and bone metastasis in vitro and in vivo. They found that MTA1 silencing diminished formation of bone metastases and impaired tumor growth in intracardiac and subcutaneous prostate cancer xenografts, respectively. [Mol Oncol] Abstract | Full Article

Embigin Promotes Prostate Cancer Progression by S100A4-Dependent and -Independent Mechanisms

As embigin’s roles in cancer remain elusive, researchers studied its biological functions and interaction with extracellular S100A4 in prostate cancer progression. They found by a pull-down assay that embigin is a novel receptor for S100A4, which is one of the vital cancer microenvironment milieu. [Cancers] Full Article

The Natural Compound Myricetin Effectively Represses the Malignant Progression of Prostate Cancer by Inhibiting PIM1 and Disrupting the PIM1/CXCR4 Interaction

Myricetin exerted selective cytotoxic, pro-apoptotic, and anti-metastatic effects on prostate cancer cells by inhibiting the proviral integration site for Moloney murine leukemia virus-1 (PIM1) and disrupting the PIM1/CXCR4 interaction. [Cell Physiol Biochem] Full Article

Long-Term Tumor Adaptation after Radiotherapy: Therapeutic Implications for Targeting Integrins in Prostate Cancer

To analyze the short- and long-term effects of radiation on the integrin expression, prostate cancer cells were cultured in a 3D extracellular matrix and irradiated with either a single dose of radiation or a multi-fractionated regimen. [Mol Cancer Res] Abstract

R1 Regulates Prostate Tumor Growth and Progression by Transcriptional Suppression of the E3 Ligase HUWE1 to Stabilize c-Myc

The authors reported elevated expression of R1, a c-Myc-interacting protein and transcription factor, in human prostate cancer (PCa) tissue specimens. Overexpression and knockdown of R1 in human PCa cells indicated that R1 induces cell proliferation and colony formation. [Mol Cancer Res] Abstract

Succinate Accumulation Is Associated with a Shift of Mitochondrial Respiratory Control and HIF-1α Upregulation in PTEN Negative Prostate Cancer Cells

Scientists investigated the role of succinate and its main plasma membrane transporter sodium-dependent dicarboxylate transporter member 3 in prostate cancer (PCa) cells and determined whether targeting succinate metabolism can be potentially used to inhibit PCa cell growth. [Int J Mol Sci] Full Article

Subscribe to one of our other 19 science newsletters such as Mammary Cell News & ESC & iPSC News.

ARD1/NAA10 Acetylation in Prostate Cancer

Researchers provide a general understanding of androgen receptor (AR) acetylation, with a special emphasis on ARD1, and potential therapies that may be exploited against the ARD1-AR axis for prostate cancer treatment. [Exp Mol Med] Full Article

Roles of MicroRNA in Prostate Cancer Cell Metabolism

The authors explain the roles of microRNAs in prostate cancer cell metabolism, such as glucose uptake, glycolysis and lactate secretion, lipid metabolism and interaction with signaling pathways. [Int J Biochem Cell Biol] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Minomic Announces Completion of Accrual for Clinical Study of Miltuximab^® in Prostate, Bladder and Pancreatic Cancers

Minomic International Ltd announced that it has completed enrollment and dosing of all twelve patients in its pioneering clinical trial of Miltuximab^®, a chimeric version of Minomic’s MIL-38 anti-Glypican 1 antibody conjugated to the radioactive isotope⁶⁷ Gallium. [Minomic International Ltd] Press Release

Poseida Awarded $3.99 Million CIRM Grant to Support Preclinical Development of P-PSMA-101, a T Stem Cell Memory CAR-T Therapy for Prostate Cancer

Poseida Therapeutics Inc. announced that the California Institute for Regenerative Medicine (CIRM) awarded a $3.99 million CLIN 1 grant to support the late stage preclinical development of Poseida’s P-prostate-specific membrane antigen (PSMA)-101 product candidate. [Poseida Therapeutics Inc.] Press Release

Trump Desperately Needs a Science Adviser, Experts Say. He Just Doubled the Record for Time without One

President Trump can add another tick in the records column: he doubled the length of time that any modern president has gone without a science adviser. [Washington Post] Editorial

UK-India Science Ministers Reinforce Strong Research Partnership as Future Collaboration Is Announced

The UK and Indian governments signaled their commitment to a deeper relationship by jointly announcing four new awards worth £4.8 million under the Civil Nuclear Energy program and seven new awards worth £10.8 million under Phase 2 of the Global research program on health. [GOV.UK] Editorial

NEW The 5^th Canadian Cancer Research Conference
November 3-5, 2019
Ottawa, Ontario, Canada

Visit our events page to see a complete list of events in the community.

NEW Clinical Fellow – Prostate Cancer Biology (Cancer Research UK Manchester Institute)

NEW Assistant or Associate Professor – Prostate Cancer (Lerner Research Institute of the Cleveland Clinic)

Postdoctoral Position – Tumor Ecosystem Research (University of Zurich)

Postdoctoral Felllow – Non-Coding RNA & Cancer Research (Universtiy of Toronto)

Research Fellowship – Prostate Cancer Pathology (Weill Cornell Medicine)

Postdoctoral Fellow – Prostate Cancer Metastasis Research (Oregon Health & Science University)

Postdoctoral Fellow – Molecular Mechanisms of Prostate Cancer (Northwestern University Feinberg School of Medicine)

Postdoctoral Fellow – Prostate Cancer Development & Progression Research (Brigham & Women’s Hospital-Harvard Medical School)

Postdoctoral Fellow – Cancer Research (Princess Margaret Cancer Centre)

Postdoctoral Positions – Ribosome Modifications (University of Copenhagen)

Research Fellow – Prostate Cancer (Sechenov University)

Postdoctoral Fellow – Prostate Cancer (Moffitt Cancer Center)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.